Agents Used to Treat Urological Disorders
OHARN3 “Harnalidge D tablet” 0.2 mg/tab
OHARN4“Harnalidge Ocas Prolonged Release tablets” 0.4 mg/tab
OTAML1 “Tamlosin capsule” 0.2 mg/cap
OTAML2 “Tamlosin D tablet” 0.2 mg/tab
OURNA1 “Urnal SR FC capsule” 0.2 mg/cap
適應症：前列腺肥大症(增生)所伴隨的排尿障礙。
Usual dose:
Benign prostatic hyperplasia: Initial, PO 0.4 mg qd; if no response after 2-4 wks, may increase dose to 0.8 mg qd.
Adverse effect:
Common: chest pain, rash, abdominal discomfort, abnormal taste in mouth, bitter, diarrhea, nausea, arthralgia, backache, myalgia, asthenia, dizziness, headache, insomnia, somnolence, amblyopia, abnormal ejaculation, cough, pharyngitis, rhinitis, sinusitis.
Serious: intraoperative floppy iris syndrome, priapism.
Related Entries
(Visited 105 times, 1 visits today)